Vivek Khemka

机构：Pulse Biosciences (United States)

发表论文 49 篇 · 总被引 802 次 · h-index 10

代表论文

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial (2024 · Journal of Clinical Oncology · 被引 63)
KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma. (2022 · Journal of Clinical Oncology · 被引 24)
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma (2019 · Investigational New Drugs · 被引 14)
#88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study (2024 · International Journal of Gynecological Cancer · 被引 10)
393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results (2020 · Regular and Young Investigator Award Abstracts · 被引 9)
39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer (2024 · ESMO Open · 被引 6)